Skip to main content


Page 24 of 29

  1. The aim of this study was to investigate the association between visual hallucinations in dementia with Lewy bodies (DLB) and brain perfusion using single-photon emission computed tomography.

    Authors: Camille Heitz, Vincent Noblet, Benjamin Cretin, Nathalie Philippi, Laurent Kremer, Mélanie Stackfleth, Fabrice Hubele, Jean Paul Armspach, Izzie Namer and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2015 7:6
  2. Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). Both NPS have negative effects on cognitive performance and ...

    Authors: Yannick Vermeiren, Debby Van Dam, Tony Aerts, Sebastiaan Engelborghs, Jean-Jacques Martin and Peter P De Deyn
    Citation: Alzheimer's Research & Therapy 2015 7:7
  3. The efficacy of a cholinesterase inhibitor, donepezil, in patients with dementia with Lewy bodies (DLB) was investigated to confirm the superiority over placebo in the 12-week, double-blind phase of this phase...

    Authors: Manabu Ikeda, Etsuro Mori, Kazutaka Matsuo, Masaki Nakagawa and Kenji Kosaka
    Citation: Alzheimer's Research & Therapy 2015 7:4
  4. Scarcity of resources means that difficult choices have to be made about how to use them. Cost-effectiveness evidence provides a way to help decision-makers get ‘best value’ from their resources when choosing ...

    Authors: Martin Knapp
    Citation: Alzheimer's Research & Therapy 2015 7:10
  5. Age-related vascular changes, including blood pressure elevation and cerebral blood flow (CBF) reduction, are associated with cognitive decline and Alzheimer’s disease (AD). Evidence suggests that the relation...

    Authors: Lindsay R Clark, Daniel A Nation, Christina E Wierenga, Katherine J Bangen, Sheena I Dev, David D Shin, Lisa Delano-Wood, Thomas T Liu, Robert A Rissman and Mark W Bondi
    Citation: Alzheimer's Research & Therapy 2015 7:3
  6. Recent research on biomarkers has made possible the diagnosis of pre-dementia and even preclinical Alzheimer’s disease (AD), thus providing the ideal context for prevention. The aim of this study was to invest...

    Authors: Javier Mar, Myriam Soto-Gordoa, Arantzazu Arrospide, Fermín Moreno-Izco and Pablo Martínez-Lage
    Citation: Alzheimer's Research & Therapy 2015 7:2
  7. Longitudinal assessment of cognitive decline in amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD) often involves the use of both informant-based and objective cognitive assessments. As eff...

    Authors: Michael Malek-Ahmadi, Kewei Chen, Kathryn Davis, Christine M Belden, Jessica Powell, Sandra A Jacobson and Marwan N Sabbagh
    Citation: Alzheimer's Research & Therapy 2015 7:1
  8. As the need to develop a successful disease-modifying treatment for Alzheimer’s disease (AD) becomes more urgent, imaging is increasingly used in therapeutic trials. We provide an overview of how the different...

    Authors: David M Cash, Jonathan D Rohrer, Natalie S Ryan, Sebastien Ourselin and Nick C Fox
    Citation: Alzheimer's Research & Therapy 2014 6:87
  9. Electroencephalography (EEG) is a longstanding technique to measure electrical brain activity and thereby an indirect measure of synaptic activity. Synaptic dysfunction accompanies Alzheimer’s disease (AD) and...

    Authors: Elisabeth CW van Straaten, Philip Scheltens, Alida A Gouw and Cornelis J Stam
    Citation: Alzheimer's Research & Therapy 2014 6:86
  10. Many neurodegenerative diseases are characterised by accumulations of misfolded proteins that can colocalise with chaperone proteins (for example, heat shock protein 27 (HSP27)), which might act as modulators ...

    Authors: Xuekai Zhang, Jing Shi, Jinzhou Tian, Andrew C Robinson, Yvonne S Davidson and David M Mann
    Citation: Alzheimer's Research & Therapy 2014 6:78
  11. Excessive daytime sleepiness is a commonly reported problem in dementia with Lewy bodies (DLB). We examined the relationship between nighttime sleep continuity and the propensity to fall asleep during the day ...

    Authors: Tanis J Ferman, Glenn E Smith, Dennis W Dickson, Neill R Graff-Radford, Siong-Chi Lin, Zbigniew Wszolek, Jay A Van Gerpen, Ryan Uitti, David S Knopman, Ronald C Petersen, Joseph E Parisi, Michael H Silber and Bradley F Boeve
    Citation: Alzheimer’s Research & Therapy 2014 6:76
  12. Dementia with Lewy bodies (DLB) and Corticobasal Syndrome (CBS) are atypical parkinsonian disorders with fronto-subcortical and posterior cognitive dysfunction as common features. While visual hallucinations a...

    Authors: Michael R Misch, Sara Mitchell, Philip L Francis, Kayla Sherborn, Katayoun Meradje, Alicia A McNeely, Kie Honjo, Jiali Zhao, Christopher JM Scott, Curtis B Caldwell, Lisa Ehrlich, Prathiba Shammi, Bradley J MacIntosh, Juan M Bilbao, Anthony E Lang, Sandra E Black…
    Citation: Alzheimer's Research & Therapy 2014 6:71
  13. Lewy body and Alzheimer-type pathologies often co-exist. Several studies suggest a synergistic relationship between amyloid-β (Aβ) and α-synuclein (α-syn) accumulation. We have explored the relationship betwee...

    Authors: Marta Swirski, J Scott Miners, Rohan de Silva, Tammaryn Lashley, Helen Ling, Janice Holton, Tamas Revesz and Seth Love
    Citation: Alzheimer's Research & Therapy 2014 6:77
  14. Optimal identification of subtle cognitive impairment in the primary care setting requires a very brief tool combining (a) patients’ subjective impairments, (b) cognitive testing, and (c) information from info...

    Authors: Michael M Ehrensperger, Kirsten I Taylor, Manfred Berres, Nancy S Foldi, Myriam Dellenbach, Irene Bopp, Gabriel Gold, Armin von Gunten, Daniel Inglin, René Müri, Brigitte Rüegger, Reto W Kressig and Andreas U Monsch
    Citation: Alzheimer's Research & Therapy 2014 6:69
  15. The spectrum of mixed brain pathologies expands beyond accompanying vascular pathology in brains with Alzheimer’s disease-related pathology. Co-occurrence of neurodegenerative non-Alzheimer’s disease-type prot...

    Authors: Jasmin Rahimi and Gabor G Kovacs
    Citation: Alzheimer’s Research & Therapy 2014 6:82
  16. The β-secretase enzyme, β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), cleaves amyloid precursor protein (APP) in the first step in β-amyloid (Aβ) peptide production. Thus, BACE1 is a key target f...

    Authors: Erik Portelius, Robert A Dean, Ulf Andreasson, Niklas Mattsson, Anni Westerlund, Maria Olsson, Ronald Bradley Demattos, Margaret M Racke, Henrik Zetterberg, Patrick C May and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2014 6:75
  17. Two methods of non-invasive brain stimulation, transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), have demonstrable positive effects on cognition and can ameliorate neu...

    Authors: Greg J Elder and John-Paul Taylor
    Citation: Alzheimer's Research & Therapy 2014 6:74
  18. Recently, a whole-exome sequencing (WES) study showed that a rare variant rs145999145 composed of p.Val232Met located in exon 7 of the phospholipase D3 (PLD3) gene confers a doubled risk for late-onset Alzheimer’...

    Authors: Jun-ichi Satoh, Yoshihiro Kino, Yoji Yamamoto, Natsuki Kawana, Tsuyoshi Ishida, Yuko Saito and Kunimasa Arima
    Citation: Alzheimer's Research & Therapy 2014 6:70
  19. α-Synuclein is an abundantly expressed neuronal protein that is at the center of focus in understanding a group of neurodegenerative disorders called α-synucleinopathies, which are characterized by the presenc...

    Authors: Woojin Scott Kim, Katarina Kågedal and Glenda M Halliday
    Citation: Alzheimer's Research & Therapy 2014 6:73
  20. Therapeutic education is expanding in the management of Alzheimer’s disease (AD) patients. Several studies have revealed a positive impact of therapeutic educational programmes on the caregiver’s burden and/or...

    Authors: Hélène Villars, Virginie Gardette, Amélie Perrin, Christophe Hein, Sophie Elmalem, Eva de Peretti, Audrey Zueras, Bruno Vellas and Fati Nourhashémi
    Citation: Alzheimer's Research & Therapy 2014 6:66
  21. The identification of early, preferably presymptomatic, biomarkers and true etiologic factors for Alzheimer’s disease (AD) is the first step toward establishing effective primary and secondary prevention progr...

    Authors: Oscar Sotolongo-Grau, Pedro Pesini, Sergi Valero, Asunción Lafuente, Mar Buendía, Virginia Pérez-Grijalba, Itziar San Josè, Marta Ibarria, Miguel A Tejero, Joan Giménez, Isabel Hernández, Lluís Tárraga, Agustín Ruiz, Mercè Boada and Manuel Sarasa
    Citation: Alzheimer's Research & Therapy 2014 6:56
  22. Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, si...

    Authors: Sebastian Schade and Brit Mollenhauer
    Citation: Alzheimer's Research & Therapy 2014 6:72
  23. Diagnostic effectiveness of Ioflupane I 123 injection (DaTSCANTM, DaTscanTM, or [123I]FP-CIT or ioflupane [123I]) SPECT imaging, was assessed in patients with clinically uncertain parkinsonian syndrome (CUPS).

    Authors: Nin Bajaj, Robert A Hauser, John Seibyl, Andreas Kupsch, Michail Plotkin, Chris Chen and Igor D Grachev
    Citation: Alzheimer's Research & Therapy 2014 6:67
  24. Compared to Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) is usually associated with a more complex clinical picture and higher burden of care. Yet, few investigations have been performed on comorb...

    Authors: Seyed-Mohammad Fereshtehnejad, Soheil Damangir, Pavla Cermakova, Dag Aarsland, Maria Eriksdotter and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2014 6:65
  25. The long-term consequences of repetitive head impacts have been described since the early 20th century. Terms such as punch drunk and dementia pugilistica were first used to describe the clinical syndromes exp...

    Authors: Philip H Montenigro, Christine M Baugh, Daniel H Daneshvar, Jesse Mez, Andrew E Budson, Rhoda Au, Douglas I Katz, Robert C Cantu and Robert A Stern
    Citation: Alzheimer's Research & Therapy 2014 6:68
  26. Many age-related health problems have been associated with dementia, leading to the hypothesis that late-life dementia may be determined less by specific risk factors, and more by the operation of multiple hea...

    Authors: Xiaowei Song, Arnold Mitnitski and Kenneth Rockwood
    Citation: Alzheimer's Research & Therapy 2014 6:54
  27. The aim of this review was to investigate whether there is a faster cognitive decline in dementia with Lewy bodies (DLB) than in Alzheimer’s disease (AD) over time.

    Authors: Monica H Breitve, Luiza J Chwiszczuk, Minna J Hynninen, Arvid Rongve, Kolbjørn Brønnick, Carmen Janvin and Dag Aarsland
    Citation: Alzheimer's Research & Therapy 2014 6:53
  28. The association of military blast exposure and brain injury was first appreciated in World War I as commotio cerebri, and later as shell shock. Similar injuries sustained in modern military conflicts are now c...

    Authors: Lee E Goldstein, Ann C McKee and Patric K Stanton
    Citation: Alzheimer's Research & Therapy 2014 6:64
  29. Since the launch in 2003 of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the USA, ever growing, similarly oriented consortia have been organized and assembled around the world. The various accompl...

    Authors: Victor L Villemagne, Seong Yoon Kim, Christopher C Rowe and Takeshi Iwatsubo
    Citation: Alzheimer's Research & Therapy 2014 6:62
  30. The biological basis of cognitive impairment in parkinsonian diseases is believed to be multifactorial. We investigated the contribution of dopamine deficiency to cognition in Parkinson disease (PD) and dement...

    Authors: Marta Marquie, Joseph J Locascio, Dorene M Rentz, J Alex Becker, Trey Hedden, Keith A Johnson, John H Growdon and Stephen N Gomperts
    Citation: Alzheimer's Research & Therapy 2014 6:52
  31. Despite widespread use of second-generation cholinesterase inhibitors for the symptomatic treatment of Alzheimer’s disease (AD), little is known about the long term effects of cholinergic treatment on global c...

    Authors: Pearl Behl, Jodi D Edwards, Alexander Kiss, Krista L Lanctot, David L Streiner, Sandra E Black and Donald T Stuss
    Citation: Alzheimer's Research & Therapy 2014 6:48
  32. Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance imaging (MRI) of patients with Alzheimer’s disease (AD) and normal elderly controls. Although the presence o...

    Authors: Joel Ramirez, Alicia A McNeely, Christopher JM Scott, Donald T Stuss and Sandra E Black
    Citation: Alzheimer's Research & Therapy 2014 6:49
  33. Pathologically modified tau protein is the main feature of Alzheimer’s disease (AD) and related tauopathies. Therefore, immunotherapies that target mis-disordered tau represent a promising avenue for the disea...

    Authors: Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Rostislav Skrabana and Michal Novak
    Citation: Alzheimer's Research & Therapy 2014 6:45
  34. We have identified structural determinants on tau protein that are essential for pathological tau–tau interaction in Alzheimer’s disease (AD). These regulatory domains, revealed by monoclonal antibody DC8E8, r...

    Authors: Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Petr Novak and Michal Novak
    Citation: Alzheimer's Research & Therapy 2014 6:44
  35. This review provides perspectives on the utility of magnetic resonance imaging (MRI) as a neuroimaging approach in the development of novel treatments for Alzheimer’s disease. These considerations were generat...

    Authors: Emilio Merlo Pich, Andreas Jeromin, Giovanni B Frisoni, Derek Hill, Andrew Lockhart, Mark E Schmidt, Martin R Turner, Stefania Mondello and William Z Potter
    Citation: Alzheimer's Research & Therapy 2014 6:51
  36. The aim of this investigation was to assess the effect of galantamine, an acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors, on brain atrophy in individuals with mild cognitive imp...

    Authors: Niels D Prins, Wiesje A van der Flier, Dirk L Knol, Nick C Fox, H Robert Brashear, Jeffrey S Nye, Frederik Barkhof and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2014 6:47
  37. Alzheimer’s disease (AD) is the major cause of dementia among the elderly. Finding blood-based biomarkers for disease diagnosis and prognosis is urgently needed.

    Authors: Oscar Alzate, Cristina Osorio, Robert M DeKroon, Ana Corcimaru and Harsha P Gunawardena
    Citation: Alzheimer's Research & Therapy 2014 6:43
  38. Levels of amyloid-beta monomer and deposited amyloid-beta in the Alzheimer’s disease brain are orders of magnitude greater than soluble amyloid-beta oligomer levels. Monomeric amyloid-beta has no known direct ...

    Authors: William F Goure, Grant A Krafft, Jasna Jerecic and Franz Hefti
    Citation: Alzheimer's Research & Therapy 2014 6:42